SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

CStone Reports CS2009 Clinical Validation, Plans Phase III Trials

CStone said CS2009 achieved proof of mechanism, safety and concept based on data from more than 300 patients across solid tumors, including NSCLC and mCRC. The company is preparing global Phase III registrational trials and discussing partnerships.

2616

Related stories